Sheldon Litwin MD
Heart Failure & Transplantation, Cardiothoracic Imaging, Non-Invasive Cardiology
Professor
Dr. Litwin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- I am a board certified general cardiologist with clinical focus in management of heart failure with preserved ejection fraction. I am very involved in the related areas of weight management and cardiometabolic disorders. I oversee multiple clinical trials in HFpEF and have been a top enroller in several recent trials (REDUCE LAP HF1, REDUCE LAP HF 2, DELIVER). I also direct the adult echocardiography laboratory at MUSC. I hold the Alicia Spaulding-Paolozzi endowed chair in cardiac imaging.
Education & Training
- Beth Israel Deaconess Medical CenterFellowship, Cardiovascular Disease, 1990 - 1993
- University of Arizona College of Medicine-PhoenixResidency, Internal Medicine, 1981 - 1984
- Washington University in St. Louis School of MedicineClass of 1981
Certifications & Licensure
- AZ State Medical License 1986 - Present
- UT State Medical License 1993 - 2026
- SC State Medical License 2014 - 2025
- WY State Medical License 2006 - 2025
- ID State Medical License 2006 - 2022
- FL State Medical License 2014 - 2016
- GA State Medical License 2010 - 2016
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Cardiovascular Disease
Clinical Trials
- REDUCE LAP-HF TRIAL II Start of enrollment: 2017 Jun 01
- A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial Start of enrollment: 2021 Apr 20
Publications & Presentations
PubMed
- Novel Controlled Metabolic Accelerator for Obesity-Related HFpEF: The HuMAIN-HFpEF Randomized Clinical Trial.Ambarish Pandey, Gregory D Lewis, Barry A Borlaug, Sanjiv J Shah, Andrew J Sauer
JAMA Cardiology. 2025-03-12 - 2 citationsEffects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity.Michael R Zile, Barry A Borlaug, Christopher M Kramer, Seth J Baum, Sheldon E Litwin
Circulation. 2025-03-11 - 1 citationsChanges in Stressed Blood Volume With Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure With Preserved Ejection Fraction: The REBALANCE-HF T...Husam M Salah, Marat Fudim, Barry A Borlaug, Sheldon E Litwin, Matthew Stark
Journal of Cardiac Failure. 2025-02-13
Press Mentions
- Prioritizing Health | Obesity and Inactivity: A Deadly Duo for Heart HealthApril 3rd, 2025
- Corvia Medical Announces Three-Year Clinical Trial Results Confirming Significant and Durable Benefits of the Corvia Atrial Shunt in Heart Failure PatientsOctober 25th, 2024
- Weight Loss, Especially with Surgery, Tied to Lower Risk of Heart FailureMarch 16th, 2017
- Join now to see all
Professional Memberships
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: